- Presentations
- 0
- Brands
- 0
- Manufacturers
- 0
- Available from stock
- 0
Vysribli is a medicine. It is available for export supply from India to licensed hospitals, importers and physicians, with the documents the destination country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- ATC classification
- M05BX04 Denosumab · Bone disease treatments, subgroup M05B, subgroup M05BX
- US FDA first approval
- Not recorded
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Biologic
- Yes
All presentations
No presentations of Vysribli are listed yet. Ask us to source it
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Vysribli available for export from India?
No presentation of Vysribli is listed yet, but our sourcing team can check licensed channels. Send a request with the strength, quantity and destination country.
Is Vysribli authorised in the European Union?
Yes. Vysribli has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Vysribli need cold chain shipping?
No listed presentation of Vysribli is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Vysribli in?
Vysribli is classified under ATC code M05BX04 (Denosumab).
References
- Vysribli (previously Denosumab Intas): European public assessment report (EPAR). European Medicines Agency. Retrieved 24 April 2026
Request Vysribli for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.